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ABSTRACT 
Erectile dysfunction (ED) is a common type of male sexual dysfunction that has a negative impact on the quality of 
life. Erectile dysfunction is common in men and the incidence increases with age. Erectile dysfunction can be 
caused by organic disorders, such as hormonal disorders and metabolic disorders. In this case report, the authors 
report the case of a man who developed chronic renal failure with multiple metabolic disorders and hypogonadism. 
This case report described the benefits of Li-ESWT therapy in patients who less responsive after receiving PDE-5 
inhibitor therapy, tadalafil as first-line therapy for erectile dysfunction. This case report was evaluated using the IIEF-
5 questionnaire and EHS score as a description of erection quality with PSV parameters from the results of penile 
CDUS during flaccid and VEGF parameters as angiogenesis factors. In this case report, the patient experienced 
improvements in erection quality, PSV parameters, and VEGF parameters after receiving Li-ESWT therapy. 
Keywords: erectile dysfunction, chronic renal failure, Li-ESWT, tadalafil, PSV, VEGF. 
ABSTRAK 
Disfungsi ereksi (DE) adalah jenis disfungsi seksual pria yang berdampak negatif pada kualitas hidup. Disfungsi 
ereksi sering terjadi pada pria dan insidensinya meningkat seiring bertambahnya usia. Disfungsi ereksi dapat 
disebabkan oleh gangguan organik, seperti gangguan hormonal dan gangguan metabolisme. Dalam laporan kasus 
ini, penulis melaporkan kasus seorang pria yang mengembangkan gagal ginjal kronis dengan beberapa gangguan 
metabolisme dan hipogonadisme. Laporan kasus ini menggambarkan manfaat terapi Li-ESWT pada pasien yang 
kurang responsif setelah mendapat terapi penghambat PDE-5, tadalafil sebagai terapi lini pertama untuk disfungsi 
ereksi. Laporan kasus ini dievaluasi menggunakan kuesioner IIEF-5 dan skor EHS sebagai gambaran kualitas ereksi 
dengan parameter PSV dari hasil CDUS penis saat lembek dan parameter VEGF sebagai faktor angiogenesis. 
Dalam laporan kasus ini, pasien mengalami peningkatan kualitas ereksi, parameter PSV, dan parameter VEGF 
setelah menerima terapi Li-ESWT. 
Kata kunci: disfungsi ereksi, gagal ginjal kronik, Li-ESWT, tadalafil, PSV, VEGF. 
 
INTRODUCTION 
Erectile dysfunction (ED) is the inability 
to achieve or sustain an erection sufficient for 
satisfactory sexual intercourse of at least three 
months. Erectile dysfunction is a common type 
of male sexual dysfunction that has a negative 
impact on the quality of life.1 Erectile dysfunction 
affects about 15% to 50% of men and increases 
with age.2 Erectile dysfunction is mostly caused 
by organic factors, especially in the vascular 




system. Metabolic conditions can cause erectile 
dysfunction, such as hyperglycemia, 
hypercholesterolemia, and hypertension.3–5 
These conditions are commonly found in 
chronic renal failure (CRF). Chronic renal failure 
causes hypertension which interrupts blood flow 
to the microvascular system, which is known as 
hypertensive angiopathy. The process of 
hypertensive angiopathy can disrupt the penile 
tissue which causing disturbances in the quality 
of the erection. Chronic renal failure can also 
lead to decreased levels of androgens or 
hypogonadism.6 
Erectile dysfunction with hypogonadism 
has the main treatment, namely androgen 
hormone substitution therapy for hypogonadism 
conditions. The first line of therapy for erectile 
dysfunction is phosphodiesterase type 5 
inhibitor (PDE-5 inhibitor).7,8 PDE-inhibitor 
therapy can be given in two ways when it is 
needed or given regularly every day. Regular 
administration of PDE-5 inhibitor therapy every 
day is known to have a better effect than the one 
taken when it is needed. PDE-5 inhibitor therapy 
has a mechanism of action by making 
vasodilation of blood vessels, so that blood flow 
is better and the quality of erection is 
improved.9–11 This therapy only makes blood 
vessels vasodilated without repairing damaged 
blood vessel endothelium. Erectile dysfunction 
therapy has experienced many developments to 
date, one of which is developing regenerative 
therapy to repair damaged blood vessel 
endothelium due to metabolic conditions, 
including hypertensive angiopathy. 
Regenerative therapy that develops has two 
different mechanisms of action, namely 
stimulating the production of factors that will 
naturally stimulate the angiogenesis process or 
giving these factors externally, such as stem cell 
therapy, which is still experimental.7 Low-
intensity shock wave therapy or known as Low-
Intensity Extracorporeal Shockwave Therapy 
(Li-ESWT) is a therapy that has a mechanism of 
action by causing microtrauma in the vascular 
and perivascular tissues of the penis which 
stimulating internal regeneration. Vascular 
Endothelial Growth Factor (VEGF) is one of the 
angiogenesis factors stimulated by this 
therapy.12,13 Blood flow in the penile tissue can 
be seen from the Peak Systolic Velocity (PSV) 
parameters from the results of the penile Color 
Doppler Ultrasonography (CDUS) 
examination.14–16 The penile CDUS examination 
can be performed in flaccid or erection 
conditions, penile CDUS examination in flaccid 
conditions has several advantages, namely that 
it is not invasive, which makes the patient is 
more comfortable during the examination.17–19 
 
CASE REPORT 
A 52-year-old man from Sidoarjo came 
to the Andrology Clinic of Dr. Soetomo Regional 
General Hospital with complaints of decreased 
erection quality. The patient complained that he 
experienced erectile problems since he was 
diagnosed with chronic renal disease and 
undergoing hemodialysis for five months before 
visiting the Andrology clinic. The decline in 
erection quality occurs slowly. The erection 
quality assessment using the Erection Hardness 
Score (EHS) at the initial visit was found to be 
consistent with the EHS score of 1 indicates that 
the penis is larger than normal, but not hard. 
Nocturnal Penile Tumescence (NPT) is still felt, 
but the frequency is quite rare and the quality is 
not good. The International Index of Erectile 
Function (IIEF) questionnaire could not be 
assessed because the patient had not have sex 
for the last three months. Furthermore, the 




patient also complained about a decrease in sex 
drive. The patient has clinical manifestations of 
a Partial Androgen Deficiency in Aging Men 
(PADAM) score. Apart from suffering from 
chronic renal disease, the patient also had a 
history of hypertension, heart failure, 
hyperuricemia, and dyslipidemia. The patient is 
also a light smoker, but this smoking habit has 
been stopped since five years ago. Regular 
treatment is carried out from the internal 
medicine department, the patient receives 
several routine medications such as Bisoprolol, 
Candesartan, Allopurinol, and Atorvastatin. 
Patients also undergo regular hemodialysis 
twice a week. 
In general, the results of the physical 
examination found that the patient was a grade 
2 obese male with a Body Mass Index (BMI) 
score of 32.2 kg/m2. Physical examination of 
other organs showed no abnormalities. The 
results of the genital examination showed that 
the size of the right and left testicles were 15cc 
and 15cc with the consistency of testicles being 
elastic. The results of laboratory tests showed 
hemoglobin 10.3 g/dL, hematocrit 31.1%, urea 
203 mg/dL, serum creatinine levels reached 
14.31 mg/dL, testosterone levels 181.8 ng/dL, 
and levels of Prostate Specific Antigen (PSA) 
0.402 ng/mL.  
The patient received short-acting 
Testosterone (Sustanon®) injection 250 mg 
using IM procedure every two weeks and 
Phosphodiesterase type 5 inhibitor (PDE-5 
inhibitor) drug in the form of Tadalafil (Cialis®) 1 
x 5 mg. Hemodialysis is still carried out 
according to the schedule determined by the 
internal medicine department. The results from 
the evaluation of therapy for 10 weeks showed 
an increase in the quality of erection and 
improvement in patient’s self-confidence, the 
EHS score increased to 2, with laboratory 
results of hemoglobin 11.7 g/dL, hematocrit 
36.5%, urea 131 mg/dL, serum creatinine 12.37 
mg/dL, testosterone 1174 ng/dL, and PSA 0.49 
ng/mL. The patient admits that he has tried to 
have sex with his partner again. 
Based on the results, adjustments were 
made to the therapy given to the patient in the 
form of adjusting the duration of the injection of 
Short-acting Testosterone (Sustanon®) 250 mg 
to every three weeks, the PDE-5 inhibitor drug, 
Tadalafil (Cialis®) to 1 x 2.5 mg, and Li-ESWT 
therapy was added. Li-ESWT therapy uses tools 
from the BTL-6000 Topline SWT with an energy 
density of 0.09 mJ/mm2, a frequency of 5Hz, 
600 shock waves per point, with a total of five 
points (the distal, medial, and proximal penile 
corpus, and in the crux dextra, and sinistra), with 
a duration of three minutes per point. Li-ESWT 
therapy was carried out twice per week for four 
weeks. The patient did not experience any side 
effects from Li-ESWT therapy. VEGF 
examination of the patient’s blood and penis 
Color Doppler Ultrasonography (CDUS) to 
determine the peak systolic velocity (PSV) in the 
cavernous arteries during the flaccid condition 
was performed before and after undergoing the 
Li-ESWT therapy program. The quality of the 
patient’s erection according to the EHS score 
was 2, and the IIEF-5 questionnaire had a result 
of 13 before receiving the Li-ESWT therapy 
program. The patient experienced an 
improvement in erectile quality after four weeks 
of Li-ESWT therapy with an EHS score of 4, 
IIEF-5 to 25, and a positive NPT. Penile CDUS 
examination with the results of the PSV 
parameter increased from 10.8 cm/second 
before Li-ESWT therapy to 13.95 cm/second 
after therapy. This is also supported by the 
increase in VEGF parameters from the results 
of blood plasma tests from 30.18 pg/mL to 67.56 
pg/mL after receiving therapy




Table 1. Condition of the erection quality and initial laboratory results 
and after 10 weeks of therapy 
 Initial Condition After 10 week of Therapy 
EHS 1 2 
IIEF-5 - 13 
NPT rare rare 
Hemoglobin 10.3 g/dL 11.7 g/dL 
Hematocrit 31.1 % 36.5 % 
Ureum 203 mg/dL 131 mg/dL 
Creatinine 14.31 mg/dL 12.37 mg/dL 
Testosterone 181.8 ng/dL 1174 ng/dL 
PSA 0.402 ng/mL 0.49 ng/mL 
 
Table 2. Evaluation results of erection quality, PSV parameters, and VEGF parameters before and 
after combination therapy with Li-ESWT for four weeks 
 Before Li-ESWT Before Li-ESWT 
EHS 2 4 
IIEF-5 13 25 
NPT Rare Always 
PSV* 10.8 cm/second 13.95 cm/second 
VEGF 30.18 pg/mL 67.56 pg/mL 
DISCUSSION 
In this case, there are many other 
conditions that comorbid to chronic renal failure 
including hypertension, heart failure, 
hyperuricemia, dyslipidemia, anemia, obesity 
grade 2, hypogonadism, and smoking habits. In 
the initial condition, the patient came to the 
andrology clinic and had received routine 
hemodialysis therapy twice a week with medical 
therapy in the form of bisoprolol, candesartan, 
allopurinol, and atorvastatin. 
The conditions that occur in this case 
have a great influence on worsening the quality 
of the patient’s erection. Uncontrolled 
hypertension can damage the microvascular 
system in the penis.20 The condition of 
dyslipidemia can lead to plaque or 
atherosclerosis which interferes with the 
elasticity of blood vessels.21 Conditions of 
anemia and heart failure can cause a decrease 
in oxygen supply to the tissues.22,23 
Hypogonadism will cause a decrease in sexual 
desire or libido, along with impaired erection 
quality.24,25 Obesity can worsen the 
hypogonadism condition.26–28 Smoking habits 
can also increase Reactive Oxygen Species 
(ROS) levels which can damage the 
endothelium of blood vessels and impairs the 
elasticity.29 Medical therapy that is taken 
regularly also has a role in worsening erection 
quality, such as bisoprolol.30 
The patient is given androgen hormone 
substitution therapy in the form of a short-acting 
Testosterone (Sustanon®) injection every two 
weeks and a PDE-5 inhibitor drug in the form of 
Tadalafil (Cialis®) 5 mg daily after a complete 
assessment. The patient experienced an 
improvement in the erection quality, but not hard 
enough for penetration after receiving therapy 
for 10 weeks. This indicates that the damage 
that occurs to the erectile tissue of the penis is 
severe enough that it does not respond to 
androgen substitution therapy and PDE-5 
inhibitors that have been given. 
Based on the results after 10 weeks of 
therapy, the patient was given an adjustment to 




the therapy given including the duration of 
androgen substitution therapy to three weeks 
due to supraphysiological testosterone levels, 
and administration of additional regenerative 
therapy, namely Li-ESWT. PDE-5 inhibitor 
(Cialis®) therapy was also reduced to 2.5 mg 
daily. Combination therapy was carried out for 
four weeks and re-evaluated. The results of the 
combined post-therapy evaluation showed that 
the patient experienced an improvement in 
erection quality. The improvement in erection 
quality occurred at the end of the second week 
after therapy. This occurs according to theory, 
namely an increase in the levels of 
angiogenesis VEGF factor after undergoing two 
weeks of therapy. Angiogenesis factors will 
stimulate neovascularization, resulting in 
improved blood flow. This can be evaluated by 
an increase in the PSV parameters. According 
to the theory, this can be detected after four 
weeks of therapy. The patient had a significant 
increase in PSV parameters from the penile 
CDUS examination of the cavernous arteries at 
the end of the fourth week. 
CONCLUSION 
Li-ESWT therapy improves the quality 
of erection in the patient who is less responsive 
after receiving first-line therapy, namely the 
PDE-5 inhibitor. Li-ESWT therapy is one of the 
combination therapy that can be given to the 
patient with erectile dysfunction. 
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